Currently out of the existing stock ratings of Michael Freeman, 17 are a BUY (85%), 3 are a HOLD (15%).

Michael Freeman

Work Performance Price Targets & Ratings Chart

Analyst Michael Freeman, currently employed at RAYMOND JAMES, has had 34.38% of price targets met with an average potential upside of 20.17%, reached in 37 days on average.

Michael Freeman has documented 39 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TECX, Tectonic Therapeutic at 25-May-2026.

Wall Street Analyst Michael Freeman

Analyst best performing recommendations are on WVE (WAVE LIFE SCIENCES LTD).
The best stock recommendation documented was for WVE (WAVE LIFE SCIENCES LTD) on 12/8/2025. The price target of $21 was fulfilled within 1 day with a profit of $2.48 (13.39%), with a performance score of 133.91.

Average potential price target upside

BHC Bausch Health Companies DYN Dyne Therapeutics IRON Disc Medicine PROF Profound Medical Corp WVE Wave Life Sciences Ltd RNA Avidity Biosciences TECX Tectonic Therapeutic

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 09-Dec-2025

$9

$0.78 (9.49%)

$7

10 days ago
(11-Nov-2026)

5/10 (50%)

$0.65 (7.78%)

148

Hold Since 01-Sep-2022

$9

$4.24 (89.08%)

$10

6 months 25 days ago
(27-Apr-2026)

13/26 (50%)

$3.42 (61.29%)

164

Hold Since 25-Jul-2024

$8

$3.24 (68.07%)

$7

10 months 14 days ago
(07-Jan-2026)

1/2 (50%)

$0.1 (1.27%)

53

Hold Since 10-Jul-2024

$8

1 years 6 months 16 days ago
(05-May-2025)

2/2 (100%)

$3.07 (62.27%)

86

Hold Since 22-Jan-2021

$3

2 years 3 months 19 days ago
(02-Aug-2024)

11/13 (84.62%)

$-2.63 (-46.71%)

164

Show more analysts

Please expand the browser size to see the chart

Which stock is Michael Freeman most bullish on?

Potential upside of $60.27 has been obtained for TECX (TECTONIC THERAPEUTIC)

What Year was the first public recommendation made by Michael Freeman?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?